Pentixapharm Holding AG (ETR:PTP)

Germany · Delayed Price · Currency is EUR

1.820

-0.030 (-1.62%)

Last updated: Aug 26, 2026, 2:29 PM CET

5.20% (1Y)

Market Cap	45.11M +3.9%
Revenue (ttm)	242.00K -86.5%
Net Income	-15.03M
EPS	-0.61
Shares Out	24.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,364
Open	1.830
Previous Close	1.850
Day's Range	1.815 - 1.840
52-Week Range	1.300 - 3.700
Beta	n/a
Analysts	Strong Buy
Price Target	9.27 (+409.34%)
Earnings Date	Aug 6, 2026

About Pentixapharm Holding AG

Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 binding, peptide-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2019

Employees 38

Stock Exchange Deutsche Börse Xetra

Ticker Symbol PTP

Full Company Profile

Financial Performance

In 2025, Pentixapharm Holding AG's revenue was 526,000, a decrease of -63.28% compared to the previous year's 1.43 million. Losses were -16.51 million, 26.4% more than in 2024.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for PTP stock is "Strong Buy." The 12-month stock price target is €9.27, which is an increase of 409.34% from the latest price.

Price Target

€9.27

(409.34% upside)

Analyst Consensus: Strong Buy

Stock Forecasts